Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023 · Licensing/Option · $9.5B · Complete
Announcement Sentiment
73
Positive
Merck and Kelun-Biotech entered an exclusive license and collaboration agreement for seven investigational preclinical ADC candidates for cancer. Kelun-Biotech received $175M upfront plus an undisclosed equity investment, with up to $9.3B in development, regulatory and sales milestones plus tiered royalties. Kelun-Biotech retains rights for mainland China, Hong Kong and Macau.